Improving the quality and efficiency of follow-up after curative treatment for breast cancer - rationale and study design of the MaCare trial

被引:18
|
作者
Kimman, Merel L. [1 ]
Voogd, Adri C.
Dirksen, Carmen D.
Falger, Paul
Hupperets, Pierre
Keymeulen, Kristien
Hebly, Marlene
Dehing, Cary
Lambin, Philippe
Boersma, Liesbeth J.
机构
[1] Maastro Clin, Maastricht, Netherlands
[2] Maastricht Univ, Dept GROW MAASTRO, Maastricht, Netherlands
[3] Maastricht Univ, Dept Epidemiol, Maastricht, Netherlands
[4] Univ Hosp Maastricht, Dept Clin Epidemiol & Med Technol Assessment, Maastricht, Netherlands
[5] Univ Hosp Maastricht, Dept Med Psychol, Maastricht, Netherlands
[6] Univ Hosp Maastricht, Dept Med Oncol, Maastricht, Netherlands
[7] Univ Hosp Maastricht, Dept Surg, Maastricht, Netherlands
[8] Univ Hosp Maastricht, Dept Radiat Oncol, Maastricht, Netherlands
关键词
D O I
10.1186/1471-2407-7-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: After curative treatment for breast cancer women frequently attend scheduled follow-up examinations. Usually the follow-up is most frequent in the first 2-3 years ( 2-4 times a year); thereafter the frequency is reduced to once a year in most countries. Its main aim is to detect local disease recurrence, or a second primary breast cancer, but also to provide information and psychosocial support. However, the cost-effectiveness of these frequent visits is under much debate, leading to a search for less intensive and more cost-effective follow-up strategies. In this paper the design of the MaCare trial is described. This trial compares the cost-effectiveness of four follow-up strategies for curatively treated breast cancer patients. We investigate the costs and effects of nurse-led telephone follow-up and a short educational group programme. Methods/design: The MaCare trial is a multi centre randomised clinical trial in which 320 breast cancer patients are randomised into four follow-up strategies, focussed on the first 18 months after treatment: 1) standard follow-up; 2) nurse-led telephone follow-up; 3) arm 1 with the educational group programme; 4) arm 2 with the educational group programme. Data is collected at baseline and 3, 6, 12 and 18 months after treatment. The primary endpoint of the trial is cancer-specific quality of life as measured by the global health/QoL scale of the EORTC QLQ-C30. Secondary outcomes are perceived feelings of control, anxiety, patients' satisfaction with follow-up and costs. A cost-effectiveness analysis will be performed from a societal perspective. Discussion: Reduced follow-up strategies for breast cancer have not yet been widely applied in clinical practice. Improvement of psychosocial support and information to patients could lead to a better acceptance of reduced follow-up. The MaCare trial combines a reduced follow-up strategy with additional psychosocial support. Less frequent follow-up can reduce the burden on medical specialists and costs. The educational group programme can improve QoL of patients, but also less frequent follow-up can improve QoL by reducing the anxiety experienced for each follow-up visit. Results of the trial will provide knowledge on both costs and psychosocial aspects regarding follow-up and are expected in 2009.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] COST OF PATIENT FOLLOW-UP AFTER POTENTIALLY CURATIVE COLORECTAL-CANCER TREATMENT
    VIRGO, KS
    VERNAVA, AM
    LONGO, WE
    MCKIRGAN, LW
    JOHNSON, FE
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (23): : 1837 - 1841
  • [42] Follow-up after curative treatment for colorectal cancer: longitudinal evaluation of patient initiated follow-up in the first 12 months
    L. Batehup
    K. Porter
    H. Gage
    P. Williams
    P. Simmonds
    E. Lowson
    L. Dodson
    N. J. Davies
    R. Wagland
    J. D. Winter
    A. Richardson
    A. Turner
    J. L. Corner
    Supportive Care in Cancer, 2017, 25 : 2063 - 2073
  • [43] Long-Term Structured Follow-up Is Essential After Curative Cancer Treatment
    Keilholz, Ulrich
    Pezzutto, Antonio
    Budach, Volker
    Eggert, Angelika
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2014, 111 (1-2): : 1 - 2
  • [44] Follow-up after curative treatment for colorectal cancer: longitudinal evaluation of patient initiated follow-up in the first 12 months
    Batehup, L.
    Porter, K.
    Gage, H.
    Williams, P.
    Simmonds, P.
    Lowson, E.
    Dodson, L.
    Davies, N. J.
    Wagland, R.
    Winter, J. D.
    Richardson, A.
    Turner, A.
    Corner, J. L.
    SUPPORTIVE CARE IN CANCER, 2017, 25 (07) : 2063 - 2073
  • [45] Follow-Up after Breast Cancer Diagnosis
    Thomssen, Christoph
    Diel, Ingo
    Gnant, Michael
    Goldmann-Posch, Ursula
    Goeschke, Christiane
    Haidinger, Renate
    Janni, Wolfgang
    Lin, Nancy U.
    BREAST CARE, 2013, 8 (06) : 457 - 460
  • [46] Patients' view of routine follow-up after breast cancer treatment
    Bjelic-Radisic, Vesna
    Dorfer, Martha
    Tamussino, Karl
    Greimel, Elfriede
    WIENER KLINISCHE WOCHENSCHRIFT, 2017, 129 (21-22) : 810 - 815
  • [47] Patients’ view of routine follow-up after breast cancer treatment
    Vesna Bjelic-Radisic
    Martha Dorfer
    Karl Tamussino
    Elfriede Greimel
    Wiener klinische Wochenschrift, 2017, 129 : 810 - 815
  • [48] Follow-up after breast cancer - National randomised controlled trial is needed
    Donnelly, Peter K.
    Hiller, Louise
    Dunn, Janet A.
    BRITISH MEDICAL JOURNAL, 2008, 336 (7642): : 461 - 462
  • [49] Follow-up study of quality of life and anxiety in patients with breast cancer
    Haertl, K.
    Adolf, B.
    Schennach, R.
    Sommer, H.
    Rammel, G.
    Friese, K.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2007, 67 (05) : 519 - 519
  • [50] Follow-up Cost of Breast Cancer Patients with Localized Disease After Primary Treatment: a Randomized Trial
    R. Kokko
    M. Hakama
    K. Holli
    Breast Cancer Research and Treatment, 2005, 93 : 255 - 260